... the advantages of non-selective COX 5.2 inhibitors/NSAIDs compared to selective COX-2 inhibitors in relieving symptoms and reducing toxicity? 6. When ...

... Whilst there is clear evidence that the more selective COX-2 inhibitors such as rofecoxib do produce fewer serious GI ... et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety ...

... yet developed appreciable muscle weakness The introduction of selective NSAIDs—COX-2 and wasting or cardiovascular deconditioning are inhibitors (e.g., celecoxib, rofecoxib) and COX-2 the ...

... upper GI bleeding/perforation is seen with non-selective NSAIDs; those with a long half-life and slow-release preparations. The highest risk is with piroxicam (RR 9.94, 95% CI 5.99 to16.50) followed by naproxen (RR 5.57, 95% CI 3.94 to 7.87) whereas COX-2 inhibitors such as celecoxib (RR 1.42, 95% CI ...

... Suppl):S749-52; discussion S753-6 Celecoxib: a COX-2 inhibitor. Andrews SA, et al. Am J Manag Care ... Med Care 1999 May; 37(5):518-25 Cox-2 inhibitors. Brown E. Physician Exec 1999 Jan-Feb;25( ...

Cyclooxygenase 2 Inhibitors -- therapeutic use ... use Cardiovascular Diseases -- drug therapy Clozapine -- therapeutic use Cyclooxygenase 2 Inhibitors -- therapeutic use Drugs, Investigational Lung Diseases -- drug therapy ...

... 6fondaparinux The synthetic pentasaccharide fondaparinux is a highly selective, indirect inhibitor of factor Xa. It is licensed ... at a therapeutic thrombolysis and/or thrombectomy with selective endovascular dose in patients with renal insufficiency. J ...